Is oral methotrexate effective for treating lichen planus pigmentosus refractory to first‑line agents such as tranexamic acid or acitretin?

Oral Methotrexate for Lichen Planus Pigmentosus: Limited Evidence but Reasonable Option

Oral methotrexate can be considered as a steroid-sparing immunosuppressant for severe or refractory lichen planus pigmentosus (LPP), though evidence is limited and it should be positioned after first-line topical therapies and oral tranexamic acid or acitretin have failed.

Evidence Base and Treatment Positioning

The evidence for methotrexate in LPP specifically is extremely limited. The 2024 NCCN guidelines 1 list methotrexate among steroid-sparing immunosuppressants (alongside azathioprine, cyclosporine, hydroxychloroquine, and mycophenolate mofetil) for severe lichen planus/lichenoid diseases, but this is based on expert consensus rather than controlled trials in LPP.

Evidence from Related Lichen Planus Variants

The strongest evidence comes from studies of other lichen planus variants:

• Erosive oral lichen planus: A prospective trial of 18 patients using methotrexate 15 mg weekly showed 83.3% achieved partial response or better, with statistically significant reductions in disease severity and pain scores 2. Another study demonstrated 58% complete remission by 24 weeks in generalized lichen planus 3.

• Cutaneous lichen planus: A systematic review found methotrexate effective with nonsignificant differences compared to oral betamethasone in achieving complete response 4. A comparative study showed 55% excellent improvement with methotrexate 7.5 mg weekly versus 85% with oral mini-pulse betamethasone 5.

• British guidelines 6 acknowledge methotrexate use for oral lichen planus based on case reports and small series, though evidence is limited to level 3.

Practical Dosing Algorithm

Starting regimen (based on psoriasis and rheumatoid arthritis guidelines 7, 8):

• Begin at 15 mg orally once weekly (not 7.5 mg, which is slower-acting)
• Consider test dose of 2.5-5 mg only if patient has renal impairment, diabetes, or significant drug interactions 7
• Mandatory folic acid supplementation: 1 mg daily on non-methotrexate days 9, 7

Route considerations:

• Oral administration preferred initially 8
• Switch to subcutaneous if insufficient response at highest tolerable oral dose (bioavailability is higher parenterally) 7, 8
• Maximum dose: 25 mg weekly 9, 7

Timeline expectations:

• Onset of effect: 8-12 weeks for lichen planus 9
• Continue for at least 12 months before tapering if acceptable improvement achieved 10

Critical Monitoring Requirements

Baseline assessment 7:

• Complete blood count, liver function tests, serum creatinine
• Pregnancy test (contraindicated in pregnancy and for 1 menstrual cycle after stopping) 7, 11
• Consider hepatology referral if baseline liver abnormalities or risk factors for hepatotoxicity

Ongoing monitoring 7:

• CBC and liver function tests every 3-6 months
• If liver enzymes ≥3× upper limit of normal for 2 consecutive months: temporarily discontinue 9
• Discontinue if WBC <3×10⁹/L, ANC <10×10⁹/L, or platelets <100,000/L 9

Important Caveats

Contraindications 7, 11:

• Absolute: pregnancy, breastfeeding, women planning pregnancy within 1 cycle of stopping
• Relative: significant hepatic disease, bone marrow suppression, chronic kidney disease

Drug interactions 9:

• NSAIDs/salicylates can be given concurrently with normal renal function 9
• Trimethoprim/sulfamethoxazole is NOT contraindicated (contrary to older teaching) 9

Common pitfalls:

• Starting at too low a dose (7.5 mg) delays response 7
• Forgetting folic acid supplementation increases GI and hepatic adverse effects 7
• Checking labs within 24 hours of methotrexate dose can falsely elevate liver enzymes 9

Alternative Positioning for LPP

Given the limited specific evidence for LPP, the treatment hierarchy should be:

1. First-line: High-potency topical corticosteroids (clobetasol 0.05%) or tacrolimus 0.1% 1
2. Second-line: Oral tranexamic acid (250-1500 mg daily, well-studied in LPP) 12, 13 or acitretin 1
3. Third-line: Methotrexate 15 mg weekly as steroid-sparing agent for severe/refractory disease
4. Alternatives at same level: Hydroxychloroquine, azathioprine, mycophenolate mofetil 1

The choice of methotrexate over other immunosuppressants is reasonable given its established safety profile in dermatology, extensive monitoring guidelines, and evidence in related lichen planus variants 6, 2, 3.